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Abstract
Background
There are limited data about the epidemiology and treatment-related outcomes associated
with capreomycin resistance in patients with XDR-TB. Capreomycin achieves high serum
concentrations relative to MIC but whether capreomycin has therapeutic benefit despite mi-
crobiological resistance remains unclear.
Methods
We reviewed the susceptibility profiles and outcomes associated with capreomycin usage
in patients diagnosed with XDR-TB between August 2002 and October 2012 in two prov-
inces of South Africa. Patients whose isolates were genotypically tested for capreomycin re-
sistance were included in the analysis.
Results
Of 178 XDR-TB patients 41% were HIV-infected. 87% (154/178) isolates contained a
capreomycin resistance-conferring mutation [80% (143/178) rrs A1401G and 6% (11/178)
were heteroresistant (containing both the rrs A1401G mutation and wild-type sequences)].
Previous MDR-TB treatment, prior usage of kanamycin, or strain type was not associated
with capreomycin resistance. 92% (163/178) of XDR-TB patients were empirically treated
with capreomycin. Capreomycin resistance decreased the odds of sputum culture conver-
sion. In capreomycin sensitive and resistant persons combined weight at diagnosis was
the only independent predictor for survival (p=<0.001). By contrast, HIV status and use of
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co-amoxicillin/clavulanic acid were independent predictors of mortality (p=<0.05). Capreo-
mycin usage was not associated with survival or culture conversion when the analysis was
restricted to those whose isolates were resistant to capreomycin.
Conclusion
In South Africa the frequency of capreomycin conferring mutations was extremely high in
XDR-TB isolates. In those with capreomycin resistance there appeared to be no therapeutic
benefit of using capreomycin. These data inform susceptibility testing and the design of
treatment regimens for XDR-TB in TB endemic settings.
Introduction
Multi-drug resistant tuberculosis (MDR-TB) is a burgeoning problem worldwide with an esti-
mated ~480 000 cases recorded globally in 2014 [1]. About 5–10% of cases of MDR-TB have
extensively drug-resistant TB (XDR-TB) and some strains have evolved to resistance beyond
XDR-TB (XXDR-TB or totally drug-resistant TB) [2–4]. Treating drug-resistant TB consumes
almost 45% of the total budget of the South African National TB Programme (NTP) [5] and
this scenario has the potential to destabilise successful TB treatment programmes in many high
burden countries. Initial optimism about reasonably good outcomes [6, 7] have been sup-
planted by more dismal data from high burden setting(s) [8–12], indicating a high mortality
and culture conversion rates of less than 20%. The factors underpinning the poor outcomes in
high burden settings compared to intermediate burden settings, are not well understood.
Patients with XDR-TB are resistant to four potent anti-TB drugs (rifampicin, isoniazid, flu-
oroquinolones and aminoglycosides) and in South Africa, resistance to the latter two drugs is
mostly acquired (i.e. a high proportion of cases have been infected with a circulating MDR-TB
strain). This in part is due to a weakened MDR-TB regimen because of the unrecognized high
level of ethionamide resistance [13]. Given that alternative drugs like linezolid are not available
to resource poor national TB programmes, therapeutic options are severely limited, and
capreomycin forms the backbone of a presumed effective empiric regimen. Although capreo-
mycin has been used since 2006 in South Africa, capreomycin susceptibility testing only be-
came more widely available after 2010 and thus the overall levels of resistance to this drug,
despite empiric use, has been poorly studied [14, 15]. Given the above-mentioned consider-
ations we reasoned that capreomycin resistance might be significant, be associated with prior
aminoglycoside usage, and may explain the poor treatment outcomes [16, 17]. Furthermore,
given that peak serum levels attained with capreomycin are well above the minimum inhibitory
concentration (MIC) [18, 19], we hypothesised that capreomycin could still have a therapeutic
benefit despite the presence of the rrs A1401G mutation conferring in vitro resistance, accord-
ing to the WHO defined critical concentration (2.5ug/ml) in MGIT media [20]. By contrast,
lack of benefit is also likely to inform patient management as we recently showed that capreo-
mycin is a toxic drug with significant morbidity and mortality [21], and an expensive drug that
may be inappropriately diverting resources away from effectively functioning segments of the
NTP [5]. Thus, defining the context-specific risk-benefit ratio of capreomycin is critical. Such
data also inform advocacy efforts to accelerate the development of new anti-TB drugs and trial
of immunotherapeutic options in patients with XDR-TB.
Capreomycin in XDR-TB
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To address these unanswered questions, we reviewed the susceptibility profiles, associated
risk factors, and treatment outcomes of patients with XDR-TB in whom bio-banked isolates
were available for rrs genotyping.
Materials and Methods
Setting and patients
We retrospectively reviewed the case records of 310 patients (>18 years) with culture proven
XDR-TB diagnosed between August, 2002 and October 2012 at two of nine dedicated provin-
cial facilities for the treatment of XDR-TB in South Africa. Data including regimens, treatment
start and stop dates, adverse-events, and treatment outcomes were recorded
Definitions and diagnosis of MDR-TB, Pre-XDR TB and XDR-TB
Pre-XDR TB is defined as resistance to rifampicin, isoniazid and either a fluoroquinolone or
a second line injectable drug (amikacin, kanamycin or capreomycin). Standard definitions for
MDR-TB and XDR-TB are outlined in the online supplement (S1.1 in S1 Definitions and
Methods).
Outcomes
Early treatment outcomes were sputum culture conversion and reversion and late treatment
outcomes were treatment cure/completion, death, default, treatment failure or transfer out.
Death was the primary outcome measure in this study. Culture conversion was defined as two
consecutive negative sputum cultures at least 30 days apart. Culture reversion was defined as
two consecutive positive sputum cultures at least 30 days apart after initial sputum culture con-
version. Death was all-cause mortality, not necessarily secondary to TB progression.
Drug susceptibility testing
Isolates underwent routine phenotypic drug susceptibility testing (DST) (rifampicin, isoniazid,
ofloxacin, amikacin and ethionamide) in the centralised NTP-designated reference laboratory
(NHLS) as previously described [22]. Drug susceptibility testing to terizidone, fluroquinolones
other than ofloxacin and para-aminosalicylic acid is unavailable within the provincial laborato-
ries. Targeted DNA sequencing of the inhA promoter and the katG, rpoB, embB, pncA, gyrA,
and rrs genes was used to identify mutations conferring resistance [2]. Based on data from a
previous study about the frequency of mutations conferring phenotypic resistance to capreo-
mycin in the rrs gene (A1401G, G1484T) and tylA gene in clinical MDR-TB, Pre-XDR TB and
XDR-TB isolates from the Eastern Cape, South Africa, the rrs A1401G mutation was selected
to identify genotypic resistance to capreomycin [15]. Thus, isolates harbouring this mutation,
including heteroresistance (presence of both the rrs A1401G mutation and wild-type rrs se-
quences), were designated as resistant. Targeted DNA sequencing of the rrs gene was used to
identify the rrs A1401G mutation [15] (See online supplement (S1.2 in S1 Definitions and
Methods) for full details). DST of the clinical isolates against capreomycin was carried out ac-
cording to the standard proportion method on Middlebrook 7H10-agar as suggested by the
National Committee on Clinical Laboratory Standards at a critical concentration of 10.0 μg/ml
[23]. Stock solutions of the drug were prepared in distilled water and sterilised by filtration
through a Millex-GV 108 syringe-driven filter with a membrane pore size of 0.22 μm. Aliquots
of stock solutions were then stored at -80°C in screw-cap polypropylene cryovials up to 6
months. Further dilutions were made in sterile distilled water as required.
Capreomycin in XDR-TB
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MIC testing against capreomycin was done using the MGIT 960 system with EpiCenter TB
eXiST software on a subset of isolates which were susceptible to capreomycin according to the
standard proportion method. A MIC equal to the critical concentration was reported as suscep-
tible, while MICs2.5 μg/ml [15] was considered resistant [18, 20]. More detailed methods are
outlined in the online supplement (S1.3 in S1 Definitions and Methods).
Molecular epidemiology
A subset of 126 isolates from patients from the Western Cape Province was genotyped by use
of spoligotyping [22].
Statistical analysis
We compared categorical variables by use of the χ2 or Fisher exact test where appropriate, and
we compared continuous variables using the Mann-Whitney U or Kruskal-Wallis tests. Uni-
variate and multivariate logistic regression analysis was used to control for confounding and
identify associates of capreomycin genotypic resistance, XDR-TB mortality and sputum culture
conversion. See online supplement (S1.4 in S1 Definitions and Methods) for further details.
Ethics Statement
Ethical approval was obtained from the University of Cape Town human research ethics com-
mittee. Patient information was anonymised and de-identified prior to analysis.
Results
Study cohort and demographic data
Between August 2002 and October 2012 57% (178/310) of the XDR-TB patients who were
commenced on treatment were genotyped for the rrs A1401G mutation. No differences in the
age, gender, ethnicity and HIV serostatus was noted between genotyped included and non-
genotyped excluded XDR-TB patients (data not shown). The median age of genotyped patients
was 33 years (IQR 27–41 years), 55% were male, 47% were of mixed ancestry and the median
weight at diagnosis was 50.4kg (Table 1). 41% of the cohort was HIV-infected with a median
CD4 count of 193 (IQR 99–379 cells/mm3) and 87% were receiving antiretroviral therapy
(ART) at XDR-TB diagnosis. Of the 126 isolates spoligotyped, 83% were the Beijing genotype
(Table 1). 60% had a previous diagnosis of MDR-TB and 13% were Pre-XDR TB. 67% of the
cohort had previous exposure to either amikacin or kanamycin. The median total number of
drugs in the regimen was 8 (IQR 7–9) and 92% of regimens were inclusive of capreomycin
(Table 1). Capreomycin resistance as per the presence of the rrs A1401G mutation was present
in the isolates from 87% (154/178) of patients who were predominantly HIV-uninfected [58%
(90/154)] (Fig 1). The demographic profile and clinical characteristics were not significantly
different when comparing isolates from patients with rrs A1404G mutation compared to wild
type (Table 1).
Capreomycin susceptibility data
We compared capreomycin phenotypic (via agar proportions method) and genotypic suscepti-
bility for 51% (91/178) of isolates (Table 2). There was concordance for capreomycin suscepti-
bility in 79% (72/91) of isolates. 16 of the 19 discordant isolates were available for further
analysis and discordance was consolidated using the MGIT 960 system (MIC shown in
Table 3). 100% of these isolates, excluding three with contaminated or non-viable MGIT 960
cultures, were reclassified as resistant (Table 3). Resistance in the 3 isolates found to be
Capreomycin in XDR-TB
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phenotypically resistant with no rrs A1401G mutation present could potentially be explained
by mutations outside the rrs region (unknown mechanisms conferring resistance) or an under-
lying population not detected by DNA sequencing.
Relationship between capreomycin susceptibility and treatment-related
outcomes
The overall cohort mortality was 53% (93/175) with three patients missing data, culture con-
version was 31% (53/174) with four patients missing data, and culture reversion was 34% (18/
53 patients that converted). 92% (141/154) of isolates with the rrs A1401G mutation received
capreomycin as part of their XDR-TB regimen while 92% (22/24) of patients with wild type rrs
isolates received capreomycin (Fig 1). When not stratified by capreomycin treatment status,
there were no significant differences in the above-mentioned short-term clinical outcomes be-
tween those with an isolate with an rrs A1404G mutation versus those with the wild type rrs
Table 1. Demographic profile, clinical characteristics and treatment related outcomes in patients with XDR-TB stratified by rrs A1401Gmutation
status.
Patient characteristic All rrs A1401G mutation rrs wild type P-value
(N = 178) n (%) (N = 154) n (%) (N = 24) n (%)
Demographics
Age, yrs, median (IQR) 33 (27–41) 33 (26–41) 31 (28–40) n/s
Male 97 (55) 85 (55) 12 (50) n/s
Mixed ancestry 84 (47) 72 (47) 12 (50) n/s
HIV-infected 73 (41) 64 (42) 9 (38) n/s
CD4 count, cells/μl, median (IQR) # 193 (99–379) 193 (99–365) 213 (112–486) n/s
Receiving anti-retroviral therapy at diagnosis 61/70 (87) 52/61 (85) 9/9 (100) n/s
Weight at diagnosis, kgs, median (IQR) 50.4 50.3 50.9 n/s
(44.4–60) (44.4–61.1) (44–57.9)
TB history—sputum culture proven
Previous MDR-TB 103 (60) 85 (57) 18 (75) n/s
Previous Pre-XDR TB† 23 (13) 21 (14) 2(8) n/s
TB strain
Beijing genotype strain 105/126 (83) 93/109 (85) 12/17 (71) n/s
Treatment exposure—ever
SLID§ 119 (67) 101 (68) 18 (75) n/s
Capreomycin 163 (92) 141 (92) 22 (92) n/s
Oﬂoxacin 110 (62) 97 (63) 13 (54) n/s
Moxiﬂoxacin 29 (16) 26 (17) 3 (13) n/s
Number of drugs in regimen, median (IQR) 8 (7–9) 8 (7–9) 8 (7–9) n/s
XDR-TB treatment outcomes ¶
Converted 53 (31) 42 (28) 11 (42) n/s
Reverted 18/53 (34) 16/42 (38) 2/11 (19) n/s
Mortality 93 (53) 78 (52) 15 (63) n/s
#4/73 HIV-infected patients missing CD4 cell count data and 3/73 patients missing ARV data.
†Previous Pre-XDR TB is deﬁned as MDR-TB plus resistance to either FQ or second line injectable drugs.
§SLID: Second-line injectable drug (either kanamycin or amikacin).
¶4/178 and 3/178 missing accurate conversion and mortality data respectively.
Abbreviations: IQR: interquartile range, n/s: not signiﬁcant (p = >0.05), n/c: not calculated.
doi:10.1371/journal.pone.0123655.t001
Capreomycin in XDR-TB
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genotype. (Table 1) However, in an analysis uncorrected for potential confounders, the mortal-
ity was significantly higher in patients (resistant and sensitive capreomycin genotype com-
bined) that did not receive capreomycin treatment compared to those that did [86% (12/14)
versus 50% (81/161), p = 0.01]. Restricted to patients with genotypic resistance mortality was
also higher in patients who did not receive capreomycin compared with those who did [83%
(10/12) versus 49% (68/139) p = 0.022] (Table 4; there were 2 patients with missing data).
Sputum culture conversion and reversion was not significantly different in any of the
capreomycin-specific susceptibility categories irrespective of capreomycin treatment (Table 4).
Fig 1. Study plan showing the relationship between capreomycin genotypic susceptibility profile
(wild type, rrsA1401Gmutation), HIV status, and proportion of participants who received
capreomycin.
doi:10.1371/journal.pone.0123655.g001
Capreomycin in XDR-TB
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Impact of strain type and HIV co-infection on capreomycin resistance
and treatment outcomes
Strain type by spoligotyping and HIV infection were not associated with capreomycin genotyp-
ic resistance (Table 1). Mortality in HIV-infected patients was significantly higher than in
HIV-uninfected patients [62% (44/71) versus 47% (49/104) p = 0.05]. Mortality in HIV-
infected patients whose isolates were capreomycin resistant was not significantly different
when compared to isolates from HIV-uninfected patients. Sputum culture conversion did not
vary significantly, when stratified by HIV sero-status and when comparing HIV-infected pa-
tients whose isolates were capreomycin resistant versus those whose isolates were capreomycin
sensitive.
Table 2. Comparison of capreomycin phenotypic and genotypic drug susceptibility.
Phenotypic DSTζ Capreomycin genotype Total
rrs A1401G rrs wild type
Sensitive 16† 10 26
Resistant 62 3* 65
Total 78 13 91
ζPhenotypic DST on Middlebrooks 7H10-agar was performed using the current critical concentration for
capreomycin of 10μg/ml (1). Phenotypic results were only available for 91/178 patients with rrs
genotyping results.
†16/19 discordant isolates that were available were re-tested using MGIT (see Table 3).
*3/19 discordant isolates may be due to mutations outside the rrs region or an underlying population not
detected by DNA sequencing.
doi:10.1371/journal.pone.0123655.t002
Table 3. Minimum inhibitory concentrations (MIC) using the MGIT 960 phenotypic drug-susceptibility method for initially genotypic resistant, phe-
notypic sensitive (agar-based) discordant capreomycin isolates.
rrs
genotype
Initial phenotypic classiﬁcation using ECOFF for capreomycin (10μg/ml) on
7H10 agar
MGIT 960 MIC (μg/
ml)
Phenotypic
reclassiﬁcation
A1401G S 10 R
A1401G/A S 5 R
A1401G S >10 R
A1401G S 5 R
A1401G S Contaminated n/r
A1401G S 5 R
A1401G S 10 R
A1401G S 5 R
A1401G S 5 R
A1401G S 5 R
A1401G S 5 R
A1401G S 10 R
A1401G S 5 R
A1401G S Contaminated n/r
A1401G S 5 R
MGIT: Microscopic growth in-tube (BD Biosciences, USA); S: Sensitive, R: Resistant, n/r: no result
doi:10.1371/journal.pone.0123655.t003
Capreomycin in XDR-TB
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Multivariate analysis and factors associated with outcomes
Mortality. In a multivariate analysis looking at predictors of mortality in the genotyped
study population, only weight at diagnosis [OR 0.935 (95% CI 0.902–0.969), p =<0.001] and
HIV infection [OR 2.9 (95% CI 1.3–6.3), p = 0.007] was associated with decreased and in-
creased odds of mortality, respectively. Neither capreomycin genotype resistance (p = 0.32)
nor capreomycin treatment (p = 0.16) had a significant impact controlling for confounders.
Similar significant predictors of mortality were noted when restricting the multivariate analysis
to i) only patients receiving capreomycin treatment and ii) only patients with capreomycin re-
sistance, with the addition of co-amoxicillin/clavulanic acid treatment as a significant predictor
of mortality in both sub-group analyses (Table 5).
Culture conversion. In the genotyped study population weight at diagnosis [OR 1.063
(95% CI 1.027–1.101), p = 0.001] was associated with an increased odds of sputum culture con-
version. By contrast, capreomycin resistance [OR 0.64 (95% CI 0.11–0.68), p = 0.007] and pre-
vious MDR-TB treatment [OR 0.45 (0.21–0.97), p = 0.04] were associated with decreased odds
of sputum culture conversion. Capreomycin in the regimen and usage of8 drugs was not sig-
nificantly associated with culture conversion. Restricting the analysis to only those receiving
capreomycin treatment, weight at diagnosis [OR 1.059 (95% CI 1.023–1.097), p = 0.001] was
associated with an increased odds of sputum culture conversion; Capreomycin resistance [OR
0.28 (95% CI 0.10–0.78), p = 0.02] was associated with a decreased odds of culture conversion
(Table 6).
On multivariate analysis, strain type, CD4 count and use of ART (the latter 2 co-variates in-
cluded in HIV-infected individuals only) did not impact the outcomes of mortality and culture
conversion.
Table 4. Mortality, sputum culture conversion and sputum culture reversion in XDR-TB patients classified by capreomycin genotype and treat-
ment status.
Capreomycin genotype Mortality Sputum culture conversion Sputum culture reversion
(n/N, %) (n/N, %) (n/N, %)
Capreomycin treatment given (N = 163)
Resistant and sensitive combined (n = 163) 81/161 (50.3)* 1 50/163 (30.7) 17/50 (34.0)
rrs A1401G wild type (sensitive) (n = 22) 13/22 (59.1) 10/22 (45.5) 1/10 (10.0)
rrs A1401G (resistant) (n = 141) 68/139 (48.9)* 2 40/141 (28.4) 16/40 (40.0)
No capreomycin treatment given (N = 15)
Resistant and sensitive combined (n = 15) 12/14 (85.7)* 1 3/11 (27.3) 1/3 (33.3)
*1p = 0.011
rrs A1401G wild type (sensitive) (n = 2) 2/2 (100.0) 1/2 (50.0) 1/1 (100.0)
rrs A1401G (resistant) (n = 13) 10/12 (83.3)* 2 2/9 (22.2) 0/2 (0)
*2p = 0.022
*p-values are for χ2 testing between proportions for different capreomycin treatment status but similar genotypic DST results. Only signiﬁcant p-values
shown (p = <0.05).
1 mortality in all patients (resistant and sensitive) treated and not treated with capreomycin
2 mortality only in patients with rrs A1404G mutation treated and not treated with capreomycin
The following numbers of patients were missing mortality outcome data: i) 2/141 of isolates from patients with rrs A1401G mutations receiving
capreomycin treatment, and ii) 1/13 isolates from patients with rrs A1401G mutations not receiving capreomycin treatment. 4/13 isolates from patients with
rrs A1401G mutations not receiving capreomycin treatment are missing sputum conversion data.
doi:10.1371/journal.pone.0123655.t004
Capreomycin in XDR-TB
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Discussion
There are currently limited data on the frequency and factors associated with capreomycin re-
sistance in high burden settings. The key findings of our study were (i) a high rate (87%) of
capreomycin resistance in capreomycin-naive patients with XDR-TB despite the drug not
Table 5. Multivariate logistic regression analysis for predicators† of XDR-TBmortality in the study co-
hort with resistance to rrsA1401G.
rrs A1401G mutation present versus rrs
wild type
Variable Odds ratio (95% CI) P-value
All XDR-TB patients (n = 158/178)*
Weight at diagnosis (kgs) 0.935 (0.902–0.969) <0.001
HIV-infected 2.9 (1.34–6.3) 0.007
Capreomycin rrs resistance (A1401G mutation 0.59 (0.21–1.65) 0.32
TB drugs impacting mortality
Capreomycin 0.27 (0.04–1.67) 0.16
Moxiﬂoxacin 0.39 (0.14–1.05) 0.06
Co-amoxicillin/clavulanic acid 3.1 (1.4–6.6) 0.004
Only XDR-TB patients treated with capreomycin (n = 151/163)*
Weight at diagnosis (kgs) 0.94 (0.91–0.98) 0.001
HIV-infected 2.7 (1.2–5.9) 0.01
Capreomycin rrs resistance (A1401G mutation 0.64 (0.22–1.83) 0.4
TB drugs impacting mortality
Moxiﬂoxacin 0.4 (0.15–1.11) 0.08
Co-amoxicillin/clavulanic acid 3.2 (1.4–7.2) 0.004
Capreomycin resistant (deﬁned by rrs A1401G mutation) n = 136/154)*
Weight at diagnosis (kgs) 0.950 (0.917–0.984) 0.005
HIV-infected 2.6 (1.2–5.8) 0.02
TB drugs impacting mortality
Capreomycin 0.28 (0.04–1.87) 0.19
Moxiﬂoxacin 0.49 (0.18–1.32) 0.16
Co-amoxicillin/clavulanic acid 3.3 (1.5–7.1) 0.003
Only rrs wild type (capromycin sensitive) (n = 21/24)*
Weight at diagnosis (kgs) 0.758 (0.589–0.976) 0.03
HIV-infected 22.3 (0.29–1698.2) 0.16
TB drugs impacting mortality
Moxiﬂoxacin 0.01 (0.00–12.7) 0.2
Co-amoxicillin/clavulanic acid 6.9 (0.26–181.5) 0.25
†A priori variables included in both the univariate and mulitivariate analysis included i) Demographic and
clinical: Age, gender, ethnicity, weight at diagnosis, HIV status, CD4 cell count and ART (in HIV-infected),
previous MDR-TB treatment, previous pre-XDR diagnosis; ii) M. tuberculosis strain typing and drug-
susceptibility testing: Beijing/non-Beijing strain, phenotypic DST for second line injectables (amikacin,
kanamycin, capreomycin, streptomycin), oﬂoxacin, ethambutol, ethionamide, and capreomycin genotypying
for rrs A1401G mutant, iii) XDR-TB drug treatments: amikacin, kanamycin, capreomycin, ciproﬂoxacin,
oﬂoxacin, moxiﬂoxacin, co-amoxicillin/clavulanic, ethambutol, ethionamide, pyrazinamide, PAS, clofazime,
dapsone, thioacetone, terizidone/cycloserine.
*The total numbers of observations included in each of the multivariate outputs. Numbers differ from
previous patient group totals due to missing data. Multiple imputation was not used.
doi:10.1371/journal.pone.0123655.t005
Capreomycin in XDR-TB
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previously being used in this population, (ii) capreomycin usage in patients whose isolates
were resistant to the drug produced no detectable clinical benefit (conversion or mortality);
rather, capreomycin resistance was a marker of conversion failure, (iii) capreomycin resistance
was not associated with prior aminoglycoside usage, and (iv) despite an intensive in-patient
multi-drug regimen treatment-related outcomes of patients with XDR-TB were poor.
In the cohort as a whole capreomycin use appeared to have a survival benefit despite geno-
typic resistance. However, after correcting for potential confounders, including HIV status,
moxifloxacin and co-amoxicillin/clavulanic usage and previous MDR-TB, capreomycin usage
was not associated with beneficial treatment-related outcomes (mortality and culture conver-
sion) both overall and in those that were capreomycin resistant. We have recently shown that
capreomycin toxicity is associated with serious morbidity and mortality in patients with
XDR-TB [21]. All the drug-related adverse-event deaths were due to capreomycin (renal fail-
ure) and capreomycin made up more than half of all the drugs withdrawn [21]. Our data sug-
gest, given the substantial costs of the drug and attendant toxicity, that capreomycin DST be
routinely implemented in the NTP and those resistant to capreomycin should not be given the
drug. Given that capreomycin is universally used in XDR-TB regimens in South Africa, this
will also enable the channelling of substantial resources to more effective drugs like linezolid.
Cost awareness is critical as we recently showed that DR-TB, despite comprising<3% of the
caseload, already consumes almost 45% of the NTP budget which is not sustainable [5].
In patients with capreomycin sensitive TB, our study was not powered to make a definitive
conclusion about mortality or culture conversion, as sample numbers were small. A retrospective
Table 6. Multivariate logistic regression analysis for predicators† of XDR-TB sputum culture conver-
sion in the study cohort with resistance to rrsA1401G.
rrs A1401G mutation present versus rrs wild type
Variable Odds ratio (95% CI) P-value
All XDR patients (n = 160/178)*
Weight at diagnosis (kgs) 1.063 (1.027–1.101) 0.001
Previous MDR-TB treatment 0.45 (0.21–0.97) 0.04
HIV-infected 0.93 (0.43–2.01) 0.86
Capreomycin rrs resitance 0.64 (0.11–0.68) 0.007
Capreomycin 0.64 (0.12–3.50) 0.6
Only XDR patients treated with capreomycin (n = 153/163)*
Weight at diagnosis (kgs) 1.059 (1.023–1.097) 0.001
Previous MDR-TB treatment 0.48 (0.22–1.03) 0.06
HIV-infected 0.92 (0.42–2.01) 0.84
Capreomycin rrs resitance 0.28 (0.10–0.78) 0.02
†A priori variables included in both the univariate and mulitivariate analysis included i) Demographic and
clinical: Age, gender, ethnicity, weight at diagnosis, HIV status, CD4 cell count and ART (in HIV-infected),
previous MDR-TB treatment, previous pre-XDR diagnosis; ii) M. tuberculosis strain typing and drug-
susceptibility testing: Beijing/non-Beijing strain, phenotypic DST for second line injectables (amikacin,
kanamycin, capreomycin, streptomycin), oﬂoxacin, ethambutol, ethionamide, and capreomycin genotypying
for rrs A1401G mutant, iii) XDR-TB drug treatments: amikacin, kanamycin, capreomycin, ciproﬂoxacin,
oﬂoxacin, moxiﬂoxacin, co-amoxicillin/clavulanic, ethambutol, ethionamide, pyrazinamide, PAS, clofazime,
dapsone, thioacetone, terizidone/cycloserine.
*The total numbers of observations included in each of the multivariate outputs. Numbers differ from
previous patient group totals due to missing data. Multiple imputation was not used.
doi:10.1371/journal.pone.0123655.t006
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study in a European population found that capreomycin was favourably associated with out-
comes in patients with XDR-TB [17]. Although capreomycin is likely to have benefit in such pa-
tients, impact may be limited in the African setting as there are few additional effective drugs to
which isolates are susceptible. Isolates in our study were already resistant to rifampicin, isonia-
zid, aminoglycosides and fluoroquinolones, and given the rate of previous MDR-TB, most were
also resistant to ethionamide and terizidone (a compound of cycloserine). Thus, even in patients
with capreomycin-sensitive TB it is likely that a single potentially effective drug would have lim-
ited impact on successful outcomes in patients with extensive lung disease and few other effec-
tive drugs to which the isolate is susceptible (linezolid is not an option as this is not available to
the national TB programme).
It is unclear why the de novo capreomycin resistance rates in this capreomycin naive popu-
lation were so high. Capreomycin is known to be associated with aminoglycoside resistance
given that mutations conferring resistance to both classes of drugs are encoded by the rrs gene
[14]. However, capreomycin resistance in this cohort seemed independent of aminoglycoside
usage (25% of the cohort did not receive prior aminoglycosides). Thus, it is possible that trans-
mission of capreomycin-resistant strains led to their amplification at the community level in
the Western and Northern Cape provinces. We think this hypothesis is tenable given that a
high proportion of patients who had no prior aminoglycoside usage also had high rates of
capreomycin resistance and that person-to-person spread is the primary modality of transmis-
sion in MDR-TB with aminoglycoside resistance (80% of MDR-TB in South Africa is now due
to primary transmission) [13].
Our findings on capreomycin susceptibility and associated outcomes were independent of
HIV-status though this may represent a type 2 error. Degree of host immunosuppression in
HIV-infected patients, as measured by CD4 count, did not appear to be an important risk fac-
tor for capreomycin resistance or treatment related outcomes. Similarly, the strain type did not
impact results.
There are several limitations to our findings, including those inherent in a study with a ret-
rospective design. There is a selection bias as those without capreomycin drug susceptibility
data were excluded from the analysis. However, a sensitivity analysis showed that the excluded
population had similar characteristics to those included in the study. A second major limitation
is that there were only small numbers of patients who were capreomycin-sensitive and received
the drug. Thus, we were underpowered to directly answer this question and we can make
limited deductions about how effective the drug is in sensitive versus resistant patients (given
survival benefit in the cohort as a whole). Although this is speculative, we feel that, even in
capreomycin-sensitive patients, only one active drug is unlikely to have a sustained impact in
patients who have extensive disease and where there are no other effective therapeutic options
(although these patients also receive drugs like co-amoxicillin/clavulanic acid, clarithromycin
and clofazimine however, these are of dubious value).
In conclusion, in this retrospective study we found that there was a high rate of capreomycin
resistance, even in a population where there was no prior usage of capreomycin, and also in
those who had not received prior aminoglycosides. Further, capreomycin usage in those resis-
tant to capreomycin did not produce any beneficial therapeutic effect. Collectively, these data
suggest that rapid genotypic testing (e.g Genotype1MTBDsl that is available) should be rou-
tinely made available to the South African NTP, and that capreomycin, given its costs and tox-
icity profile, should not be used for perceived therapeutic benefit in patients resistant to the
drug (in contradistinction to current practice). Additional studies in other high burden settings
are needed to confirm our findings. These data have important implications for the optimal de-
sign of drug regimes in high burden settings, and suggest that capreomycin should not be used
in patients who have genotypic resistance to this drug. This may have important implications
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for resource allocation and costs borne by national TB programmes in high burden settings.
These data also intensify the urgency with which new anti-TB drugs need to be developed.
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